Acurx Pharmaceuticals (ACXP) AI Stock Analysis

• Market Cap: $14.87M
• Dividend Yield: N/A
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: N/A
• EPS Growth: 61.10%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.73
• Shares Outstanding: 2,855,025
• 10 Day Avg. Volume: 3,231,033
• 30 Day Avg. Volume: 1,135,368
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -507.28
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $17.00
• Price Target Upside: 511.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -3.27
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $5.00 ▲(79.86% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and elevated cash burn/financing risk). Technicals are supportive with strong trend and positive momentum, while valuation provides limited support due to non-meaningful P/E and no dividend. Earnings-call takeaways are mixed, balancing compliance and improved cash against ongoing losses and reduced R&D intensity.

Positive Factors

Intellectual property protection

Acurx has strengthened its patent estate across multiple jurisdictions, creating a durable exclusivity window for ibezapolstat and ACX-375C. Broad patents reduce competitive entry risk, support future licensing or partner negotiations, and increase the long-term commercial optionality of its antibiotic programs.

Regulatory designations & guidance

Fast Track and QIDP designations plus positive EMA guidance materially shorten development and review timelines and can provide market exclusivity incentives. These regulatory supports increase the structural probability of faster approval and a stronger commercial position versus competitors.

Low leverage / minimal debt

Acurx’s minimal debt profile reduces near-term financial obligations and interest burdens, preserving strategic flexibility. With low leverage the company can prioritize R&D or partnerships without restrictive covenants, a durable balance-sheet advantage if it secures continuing financing.

Negative Factors

Pre-revenue, persistent losses

Acurx is a pre-revenue biotech with sustained operating losses and no product cashflows. This structural absence of revenue means long-term viability depends on successful clinical outcomes or external funding; failure to commercialize would leave persistent value erosion and limited internal cash generation.

Worsening cash burn and financing risk

Significantly higher cash burn in 2025 stretches runway and raises recurrent financing needs. Reliance on equity raises or credit lines increases dilution and can delay development timelines if funding gaps occur, a durable structural vulnerability until a revenue-generating product or a major partner emerges.

Reduced R&D intensity

Material R&D cutbacks and a very small employee base constrain internal execution and may slow pivotal trial progress. Lower investment can preserve cash short-term but risks prolonging development timelines, reducing trial momentum, and weakening scientific lead versus better-funded competitors.

Acurx Pharmaceuticals Business Overview & Revenue Model

Company Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

How the Company Makes Money

As a clinical-stage company, Acurx Pharmaceuticals does not have a product approved for commercial sale and, as a result, product revenue is null. The company’s funding and reported revenue sources, if any, are primarily tied to financing activities (such as issuing equity) and potentially other non-operating sources; however, specific recurring operating revenue streams from commercial sales are null. Going forward, if ibezapolstat or other candidates are approved, the expected primary way the company would make money would be through commercialization of those antibiotics (direct sales and/or partnering arrangements such as licensing or co-promotion), but details of future commercial terms, significant partnerships that generate revenue, or royalty arrangements are null based on publicly available high-level information here.

Acurx Pharmaceuticals Financial Statement Overview

Summary

Pre-revenue profile with persistent losses and consistently negative operating/free cash flow. Cash burn worsened materially in 2025, raising financing/dilution risk despite low leverage and generally minimal debt.

Income Statement

The company reports no revenue across the annual periods provided, so operating losses are the defining feature of the income statement. Net losses persist every year and widened dramatically in 2025 (annual), indicating a sharp deterioration in profitability and earnings quality versus prior years. With no revenue base, margins are not meaningful, and the path to scale remains the key uncertainty.

Balance Sheet

Leverage appears low with essentially no debt in most years, which reduces financial risk. However, equity and assets swing materially year to year, and returns on equity are deeply negative, including an extremely weak 2024–2025 profile, highlighting ongoing value erosion from losses. The balance sheet is not over-levered, but it is heavily dependent on external funding and/or non-operating balance sheet changes given the lack of revenue.

Cash Flow

Operating cash flow and free cash flow are consistently negative, reflecting a business that consumes cash to fund operations. Cash burn worsened significantly in 2025 (annual) versus prior years, increasing financing risk despite the low debt load. Free cash flow moves in the same direction as net income (both negative), offering limited evidence of near-term self-funding capacity.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-8.09M	0.00	-14.58M	-12.09M	-12.81M
Net Income	-7.97M	-14.10M	-14.58M	-12.09M	-12.75M
Balance Sheet
Total Assets	7.69B	3.86M	7.71M	9.38M	13.25M
Cash, Cash Equivalents and Short-Term Investments	7.56B	3.71M	7.47M	9.11M	12.96M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	2.42B	3.24M	3.04M	2.06M	843.91K
Stockholders Equity	5.27B	615.12K	4.67M	7.32M	12.41M
Cash Flow
Free Cash Flow	-6.79B	-10.38M	-9.80M	-7.54M	-5.01M
Operating Cash Flow	-6.79B	-10.38M	-9.80M	-7.54M	-5.01M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	10.64B	6.62M	8.16M	3.70M	14.80M

Acurx Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Positive. The current price of 2.78 is above the 20-day moving average (MA) of 2.67, above the 50-day MA of 2.54, and below the 200-day MA of 5.03, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 67.75 is Neutral, neither overbought nor oversold. The STOCH value of 73.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACXP.

Acurx Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACXP	52 Neutral	$14.87M	-0.47	-291.07%	―	―	61.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	51 Neutral	$75.65M	-5.32	-71.26%	―	185.71%	79.03%
BRTX	44 Neutral	$4.95M	-1.09	-207.73%	―	1.70%	-111.67%
BOLT	41 Neutral	$8.91M	-0.31	-97.58%	―	-46.88%	34.83%
WINT	39 Underperform	$476.98K	―	-1302.82%	―	―	99.09%

Acurx Pharmaceuticals Corporate Events

Acurx Advances Ibezapolstat Program for Recurrent C. difficile

On March 9, 2026, Acurx Pharmaceuticals’ compensation committee approved voluntary 10% base-salary cuts for its top executives and a 10% reduction in cash retainers for non-employee directors, effective April 1, 2026, while leaving bonus targets and equity incentives unchanged. The measures align leadership pay with market conditions and the company’s operating plan, signaling a focus on cost discipline as Acurx prepares for late-stage clinical development.

Also on March 9, 2026, the company unveiled a new clinical initiative to expand ibezapolstat into recurrent C. difficile infection (rCDI), starting with an open-label pilot trial in up to 20 multiply-recurrent patients to inform a planned Phase 3 registration study. Supported by strong Phase 2 efficacy data, favorable EMA guidance, and existing FDA Fast Track and QIDP status, Acurx aims to position ibezapolstat as a potential single-agent solution for both treatment of CDI and prevention of rCDI, which could materially enhance its competitive standing in a costly, high-unmet-need market.

The most recent analyst rating on (ACXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.